Long-term safety of Gadofosveset in clinical practice

Åkesson, Michael; Lehti, Leena; Leander, Peter; Sterner, Gunnar; Wassélius, Johan

doi:10.1016/j.mri.2021.11.011

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the realm of MRI CAs, ferumoxytol currently stands as the sole clinically available blood pool agent. Gadofosveset, its only competitor and one of the GBCAs, was withdrawn from the European market in 2009 and the American market in 2017, owing to its weak market sales [ 35 ]. Since then, there has been a market void for MR blood pool CAs.…”

Section: Clinical Applications During the Blood Pool Phasementioning

confidence: 99%

Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI

Si,

Du,

Tang

et al. 2024

National Science Review

View full text Add to dashboard Cite

Contrast-enhanced magnetic resonance imaging (CE-MRI) is a pivotal tool for global disease diagnosis and management. Since its clinical availability in 2009, the off-label use of ferumoxytol for ferumoxytol-enhanced MRI (FE-MRI) has significantly reshaped CE-MRI practices. Unlike MRI that's enhanced by gadolinium-based contrast agents, FE-MRI offers advantages such as reduced contrast agent dosage, extended imaging windows, no nephrotoxicity, higher MRI time efficiency, and the capability for molecular imaging. As a leading superparamagnetic iron oxide contrast agent, ferumoxytol is heralded as the next generation of contrast agents. This review delineates the pivotal clinical applications and inherent technical superiority of FE-MRI, providing an avant-garde medical-engineering interdisciplinary lens, thus bridging the gap between clinical demands and engineering innovations. Concurrently, we spotlight the emerging imaging themes and new technical breakthroughs. Lastly, we share our own insights on the potential trajectory of FE-MRI, shedding light on its future within the medical imaging realm.

show abstract

Section: Clinical Applications During the Blood Pool Phasementioning

confidence: 99%